Continuing Research and Development Activities
First written in FY2016-Q2. 12 of 31 entries say "Restated". Latest entry: FY2026-H1.
45 other companies' latest entry also says "Other".
- FY2026-H1Increase in cash outflowsAnnual report
「Total R&D expenses incurred during the interim consolidated accounting period were ¥101 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated accounting period.」
Although there were no material changes in the status of R&D activities, R&D expenses increased from ¥90 million in the same period of the previous year to ¥101 million. - FY2025AdvancedAnnual report
「The Group (the Company and its consolidated subsidiaries) conducts R&D activities mainly in its manufacturing divisions to maintain and improve product quality, develop technology and reduce costs. Total R&D expenses for the consolidated fiscal year were ¥179 million.」
The Company continued R&D aimed at maintaining and improving quality, developing technology, and reducing costs, and R&D expenses increased from ¥168 million in the previous fiscal year to ¥179 million. - FY2025-H1Increase in cash outflowsAnnual report
「Total R&D expenses incurred during the six-month period of the current consolidated fiscal year were ¥90 million. There were no material changes in the status of the Group’s R&D activities during the six-month period of the current consolidated fiscal year.」
While there were said to be no material changes in R&D activities, R&D expenses increased from ¥83 million in the same period of the previous year to ¥90 million. - FY2024Decrease in expendituresAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥168 million.」
While R&D activities continued to maintain and improve quality, develop technology and reduce costs, R&D expenses declined from ¥172.5 million in the same period of the previous year to ¥168 million. - FY2024-H1Slight decline in spendingAnnual report
「Total R&D expenses incurred during the six-month period of the current consolidated fiscal year were ¥83 million. There were no material changes in the status of the Group’s R&D activities during the six-month period of the current consolidated fiscal year.」
While there were said to be no material changes in R&D activities, R&D expenses declined slightly from ¥84 million in the same period of the previous year to ¥83 million. - FY2024-Q1RestatedAnnual report
「Total R&D expenses incurred during the three-month period of the current consolidated fiscal year were ¥43 million. There were no material changes in the status of the Group’s R&D activities during the three-month period of the current consolidated fiscal year.」
The disclosure states that ¥43 million was spent on R&D expenses and that there were no material changes in the status of R&D activities. - FY2023-Q3Decrease in expendituresAnnual report
「Total R&D expenses incurred during the nine-month period of the current consolidated fiscal year were ¥128 million.」
While there were said to be no material changes in R&D activities, R&D expenses declined from ¥135 million in the same period of the previous year to ¥128 million. - FY2023-Q2Decrease in expendituresAnnual report
「Total R&D expenses incurred during the six-month period of the current consolidated fiscal year were ¥84 million.」
R&D expenses declined from ¥90 million in the same period of the previous year to ¥84 million. There were said to be no material changes in the status of R&D activities. - FY2023-Q1Increase in cash outflowsAnnual report
「Total R&D expenses incurred during the three-month period of the current consolidated fiscal year were ¥43 million.」
R&D expenses increased from ¥41 million in the same period of the previous year to ¥43 million. There were said to be no material changes in the status of R&D activities. - FY2022Increase in cash outflowsAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥178 million.」
R&D activities continued to maintain and improve quality, develop technology and reduce costs, and R&D expenses increased from ¥177 million in the previous year to ¥178 million. - FY2022-Q3Increase in cash outflowsAnnual report
「Total R&D expenses incurred during the nine-month period of the current consolidated fiscal year were ¥135 million.」
R&D expenses increased from ¥125 million in the same period of the previous year to ¥135 million. There were said to be no material changes in the status of R&D activities. - FY2022-Q2Increase in cash outflowsAnnual report
「Total R&D expenses incurred during the six-month period of the current consolidated fiscal year were ¥90 million.」
While there were said to be no material changes in R&D activities, R&D expenses increased from ¥88 million in the same period of the previous year to ¥90 million. - FY2022-Q1Decrease in expendituresAnnual report
「Total R&D expenses incurred during the three-month period of the current consolidated fiscal year were ¥41 million.」
While there were no material changes in the status of R&D activities, R&D expenses declined from ¥43 million in the same period of the previous year to ¥41 million. - FY2021Slight decline in spendingAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥177 million.」
R&D activities continued to maintain and improve quality, develop technology and reduce costs. R&D expenses were ¥177 million, a slight decline from ¥177,731 thousand in the previous year. - FY2021-Q3Decrease in expendituresAnnual report
「Total R&D expenses incurred during the nine-month period of the current consolidated fiscal year were ¥125 million.」
While there were no material changes in R&D activities, R&D expenses declined from ¥133 million in the same period of the previous year to ¥125 million. - FY2021-Q1RestatedAnnual report
「Total R&D expenses incurred during the three-month period of the current consolidated fiscal year were ¥43 million. There were no material changes in the status of the Group’s R&D activities during the three-month period of the current consolidated fiscal year.」
The disclosure states that ¥43 million was spent on R&D expenses and that there were no material changes in the status of R&D activities. - FY2020Decrease in expendituresAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥177 million.」
While R&D activities continued to maintain and improve quality, develop technology and reduce costs, R&D expenses declined from ¥192,867 thousand in the previous year to ¥177,731 thousand. - FY2020-Q3Decrease in expendituresAnnual report
「Total R&D expenses incurred during the nine-month period of the current consolidated fiscal year were ¥133 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period of the current consolidated fiscal year.」
While there were said to be no material changes in R&D activities, R&D expenses declined from ¥143 million in the same period of the previous year to ¥133 million. - FY2019-Q3RestatedAnnual report
「Total R&D expenses incurred during the nine-month period of the current consolidated fiscal year were ¥143 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period of the current consolidated fiscal year.」
R&D expenses of ¥143 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2019-Q2RestatedAnnual report
「Total R&D expenses incurred during the six-month period of the current consolidated fiscal year were ¥95 million. There were no material changes in the status of the Group’s R&D activities during the six-month period of the current consolidated fiscal year.」
R&D expenses of ¥95 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2019-Q1RestatedAnnual report
「Total R&D expenses incurred during the three-month period of the current consolidated fiscal year were ¥42 million. There were no material changes in the status of the Group’s R&D activities during the three-month period of the current consolidated fiscal year.」
R&D expenses of ¥42 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2018AdvancedAnnual report
「The Group (the Company and its consolidated subsidiaries) conducts R&D activities mainly in its manufacturing divisions to maintain and improve product quality, develop technology and reduce costs. Total R&D expenses for the consolidated fiscal year were ¥173 million.」
R&D activities continued to maintain and improve quality, develop technology and reduce costs, and R&D expenses totaled ¥173 million. This was an increase from approximately ¥163 million in the previous year. - FY2018-Q3RestatedAnnual report
「Total R&D expenses incurred during the nine-month period of the current consolidated fiscal year were ¥127 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period of the current consolidated fiscal year.」
R&D expenses of ¥127 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2018-Q2RestatedAnnual report
「Total R&D expenses incurred during the six-month period of the current consolidated fiscal year were ¥88 million. There were no material changes in the status of the Group’s R&D activities during the six-month period of the current consolidated fiscal year.」
R&D expenses of ¥88 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2018-Q1RestatedAnnual report
「Total R&D expenses incurred during the three-month period of the current consolidated fiscal year were ¥32 million. There were no material changes in the status of the Group’s R&D activities during the three-month period of the current consolidated fiscal year.」
R&D expenses of ¥32 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2017AdvancedAnnual report
「The Company conducts R&D activities mainly in its manufacturing divisions to maintain and improve product quality, develop technology and reduce costs. Total R&D expenses for the consolidated fiscal year were ¥162 million.」
R&D activities continued, and R&D expenses totaled ¥162 million. This was an increase from ¥137 million in the previous consolidated fiscal year. - FY2017-Q3RestatedAnnual report
「Total R&D expenses incurred during the nine-month period of the current consolidated fiscal year were ¥116 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period of the current consolidated fiscal year.」
R&D expenses of ¥116 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2017-Q2RestatedAnnual report
「Total R&D expenses incurred during the six-month period of the current consolidated fiscal year were ¥79 million. There were no material changes in the status of the Group’s R&D activities during the six-month period of the current consolidated fiscal year.」
R&D expenses of ¥79 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2017-Q1RestatedAnnual report
「Total R&D expenses incurred during the three-month period of the current consolidated fiscal year were ¥34 million. There were no material changes in the status of the Group’s R&D activities during the three-month period of the current consolidated fiscal year.」
R&D expenses of ¥34 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2016-Q3RestatedAnnual report
「Total R&D expenses incurred during the nine-month period of the current consolidated fiscal year were ¥100 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period of the current consolidated fiscal year.」
R&D expenses of ¥100 million were disclosed, and there were said to be no material changes in the status of R&D activities. - FY2016-Q2First statedAnnual report
「Total R&D expenses incurred during the six-month period of the current consolidated fiscal year were ¥67 million.」
The disclosure states the amount of R&D expenses incurred and that there were no material changes in the status of R&D activities.